← Browse by Condition
Medical Condition

fallopian tube serous adenocarcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT04919629 Phase 2
Recruiting

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Enrollment
60 pts
Location
United States
Sponsor
Roswell Park Cancer Institute
View Trial →